MEI Pharma Inc. (MEIP)
1.89
0.05 (2.72%)
At close: Apr 09, 2025, 3:50 PM
2.72% (1D)
| Bid | 1.76 |
| Market Cap | 12.62M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -38.22M |
| EPS (ttm) | -5.73 |
| PE Ratio (ttm) | -0.33 |
| Forward PE | -0.77 |
| Analyst | Hold |
| Ask | 1.89 |
| Volume | 69 |
| Avg. Volume (20D) | 9,955 |
| Open | 1.83 |
| Previous Close | 1.84 |
| Day's Range | 1.83 - 1.89 |
| 52-Week Range | 1.73 - 4.10 |
| Beta | 0.61 |
About MEIP
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cycl...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 18, 2003
Employees 28
Stock Exchange NASDAQ
Ticker Symbol MEIP
Website https://www.meipharma.com
Analyst Forecast
According to 2 analyst ratings, the average rating for MEIP stock is "Hold." The 12-month stock price forecast is $7, which is an increase of 269.53% from the latest price.
Stock Forecasts8 months ago
+21.33%
MEI Pharma shares are trading higher after the com...
Unlock content with
Pro Subscription
